Cardiovascular Journal of Africa: Vol 22 No 1 (January/February 2011) - page 55

• Coralan ® specifically reduces
heart rate without affecting
cardiac contraction1, conduction 2
or blood pressure 3
• Coralan ® has powerful
anti-anginal and
anti-ischaemic efficacy 3
• Coralan ® improves outcomes in
heart failure patients with a heart
rate above 70bpm - SHIFT 4
For full prescribing information, refer to package insert approved by medicines regulatory authority.
S3 CORALAN ® 5 mg Tablets. Ivabradine 5 mg. Reg. No. A39/7.1.4/0410
S3 CORALAN ® 7,5 mg Tablets. Ivabradine 7,5 mg. Reg. No. A39/7.1.4/4011
NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE: SERVIER LABORATORIES SOUTH AFRICA
(Pty) Ltd. Reg. No. 72/14307/07. Building Number 4, Country Club Estate, 21 Woodlands Drive, Woodmead
2191. PO Box 930, Rivonia 2128, Republic of South Africa. TEL: +27 (0) 861 700 900. FAX: +27(0)11 233 6099.
References: 1. Vilaine JP et al. J Cardiovasc Pharmacol 2003;42:688-696. 2. Camm A et al. Drugs R&D
2003;4:83-89. 3. Borer J et al. Circulation 2003;107:817-823. 4. Swedberg K et al. Lancet 2010;376:875-885.
www.servier.com
S L O W
THE BEAT
Improve the outcome
1011/1/COR/A